BioNTech’s €17 Billion War Chest Faces Its First Real Test on May 5

The numbers coming out of BioNTech’s pancreatic cancer study are the kind that make oncologists sit up. Seven out of eight patients who mounted a strong immune response to the company’s experimental mRNA vaccine, autogene cevumeran, remain alive and cancer-free six years after surgery. For a disease as notoriously lethal as pancreatic cancer, that’s a clinical outlier — even in a small trial of just 16 participants.

Those results, unveiled at the AACR congress in 2026, have turbocharged the stock. BioNTech shares have surged roughly 26 percent over the past month, hitting €94.65 at one point, before settling back to around €91.70. The rally reflects a market increasingly willing to bet on the company’s long-shot transformation from pandemic hero to oncology powerhouse.

But the real test comes on May 5, when BioNTech reports first-quarter earnings. Investors will be looking past the headline numbers — which are expected to be ugly — and straight at the pipeline.

The Cost of Reinvention

The financial picture is sobering. After a modest revenue uptick last year, management has guided for a roughly 25 percent drop in 2026 sales, to as low as €2.3 billion. The company posted a net loss of €1.14 billion for the full year 2025. Yet with a liquidity war chest of €17.2 billion, BioNTech can afford to burn cash while it pivots.

The central tension is straightforward: COVID vaccine income is shrinking fast, and oncology revenue is still years away. The company has no cancer drug sales expected in 2026. Every euro spent on R&D today is a bet that the pipeline will deliver tomorrow.

That pipeline is now the focal point. Beyond the pancreatic cancer data, BioNTech is advancing Trastuzumab Pamirtecan, an antibody-drug conjugate that has already secured accelerated approval status from the FDA. The company plans to file for full approval this year. Six major oncology data readouts are due in the near term, and by the end of 2026, BioNTech aims to have 15 phase 3 trials running.

Should investors sell immediately? Or is it worth buying BioNTech?

Cleaning House

The strategic shift is also visible in what BioNTech is shutting down. The company will close its mRNA vaccine manufacturing facility in Singapore by the end of February 2027, a clear sign that the COVID era is over. A mandated post-market surveillance study with Pfizer has also been paused due to low infection rates and insufficient enrollment.

The resources being freed up are flowing directly into oncology. The question is whether the market will reward that discipline or punish the lack of near-term revenue.

Leadership Transition Adds Uncertainty

Adding another layer of complexity, co-founders Ugur Sahin and Özlem Türeci plan to step down by the end of 2026 to launch a new mRNA innovation unit. BioNTech is already searching for successors. How the market reacts to that leadership change will become clearer after the May 5 earnings call.

Analyst Views Diverge

Wall Street is split on the stock. Morgan Stanley maintains a buy rating with a slightly raised price target of $126. Citigroup and H.C. Wainwright both see fair value at $130. BMO Capital, however, cut its target sharply from $143 to $128, flagging risks that other firms downplay.

The bull case rests entirely on the oncology pipeline. The bear case points to the gap between R&D spending and commercial revenue. On May 5, BioNTech’s management will need to convince investors that the gap is closing — not widening.